India Pharma Outlook Team | Tuesday, 17 November 2026
Biocon has secured another milestone in the US cancer biosimilar market with FDA approval for Pebrilzo (pertuzumab-qcay), its biosimilar version of Roche’s Perjeta.
The approval gives Biocon its fifth US-approved oncology biosimilar and strengthens its presence in the competitive breast cancer treatment market.
It also adds another product to the company’s efforts to expand access to affordable biologic medicines.
However, the approval does not mean an immediate US launch. A licensing agreement with Genentech sets the earliest permitted US commercial launch for the third quarter of 2028.
Pebrilzo targets HER2 receptors on cancer cells and helps to slow or stop signals that drive tumor growth. Biocon's FDA approval covers two major treatment settings for adults with HER2-positive breast cancer.
The approval expands the treatment options available for HER2-positive breast cancer. Biosimilars can also support greater competition in the biologic medicines market and potentially improve affordability. However, actual patient access will depend on commercial availability, pricing, and market adoption.
Also Read: 5 Women Leaders Driving India's Pharma and Healthcare Innovation
Pebrilzo will join four existing FDA-approved oncology biosimilars in Biocon's portfolio:
“As our fifth oncology biosimilar to receive FDA approval, Pebrilzo strengthens our anti-cancer portfolio and advances our commitment to expanding access to high-quality, affordable biologic medicines,” said Shreehas Tambe, CEO and MD, Biocon.
The company also continues to expand its oncology pipeline with proposed biosimilars for nivolumab, pembrolizumab and trastuzumab/hyaluronidase. These candidates extend its development focus across HER2-directed treatments and immuno-oncology.
Biocon had already achieved a positive regulatory milestone in Europe in September 2026, when the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended marketing authorization for its pertuzumab biosimilar under the Pebrilzo brand.
With five US-approved cancer biosimilars and additional candidates in development, Biocon continues to build its oncology business around broader treatment options, geographic expansion and affordable biologic medicines.